The document outlines essential steps and provides guidance to countries on the adoption and deployment of c-IPTp so that it is integrated into the existing health system. It draws upon best practices and lessons learned from pilot implementation experiences in eight African countries and targets st...akeholders at the national level that are involved in the provision of maternal and child services, including national and local policymakers and implementers of malaria, maternal health, child health, reproductive health and community health programmes, and nongovernmental and other organizations.
more
The Social and Behaviour Change Communication (SBCC) Strategy for the Prevention of the Re-establishment of Malaria Transmission in Timor-Leste forms part of the National Strategic Plan (NSP) for 2021–2025. The strategy aims to support Timor-Leste's efforts to sustain malaria elimination by promot...ing responsive and preventive behaviours through targeted communication and community engagement. Created in collaboration with the Ministry of Health, the WHO, the Global Fund and other stakeholders, the SBCC strategy implements recommendations from the 2020 external review of the National Malaria Programme. Building on previous BCC initiatives (2015–2020), it emphasises surveillance, diagnosis, treatment and vector control, particularly focusing on vulnerable populations. The SBCC strategy provides partners and implementers with a dynamic guide to designing context-specific communication interventions that support malaria elimination and prevent the re-establishment of transmission.
Accessed on 18/06/2025.
more
This Implementation Kit (I-Kit), developed by the Health Communication Capacity Collaborative (HC3), helps national and local stakeholders to design country-specific social and behavioural change communication (SBCC) campaigns that address the threat posed by substandard, spurious, falsified and fal...sely labelled (SSFFC) malaria medicines. These poor-quality medicines endanger lives by failing to treat malaria effectively, undermine health systems, and contribute to drug resistance.
The I-Kit provides practical guidance and resources in six sections, including global examples, campaign design elements, media engagement strategies and tools for knowledge sharing. It is intended for health promotion officers, drug regulators, communication specialists and global health partners. Drawing heavily on experiences in Nigeria, the I-Kit promotes evidence-based, context-sensitive SBCC interventions to safeguard communities against SSFFC malaria medicines and enhance treatment outcomes.
more
Report of a virtual meeting 21–23 June 2022
Relapsing malaria caused by Plasmodium vivax parasites poses a significant challenge to global malaria elimination efforts. About one third of the population remains at risk of contracting P. vivax malaria, and 85% of P. vivax infections stem from reactivated latent parasites, leading to chronic ana...emia and increased morbidity and mortality. In addition to diagnostic tools that can detect the acute, blood-stage of P. vivax, new tools are needed to detect the dormant infections before they reactivate and contribute to morbidity and onwards transmission
more
Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV prevention overall, as it allows people to choose a method that they prefer.
In this guideline, WHO recommends an offering long-acting injectable lenacapavir (LEN...) as an additional HIV prevention choice, as part of combination HIV prevention approaches. LEN, administered twice a year as PrEP, has been shown to be highly effective at reducing the risk of HIV acquisition. In this guideline, WHO also recommends using HIV rapid diagnostic tests (RDTs) for individuals initiating or continuing long-acting injectable PrEP, such as LEN and long acting injectable cabotegravir (CAB-LA). Flexible HIV testing approaches are essential for ensuring that testing does not become a barrier to accessing or continuing PrEP, including long-acting injectable options.
more
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex B
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex D
This global guidance was developed to support malaria-free countries and those that are close to malaria elimination to prevent re-establishment. The document outlines key concepts and principles for preventing re-establishment and provides guidance on strategies, interventions, planning and managem...ent. Country examples are included to highlight good practices and illustrate practical applications.
more
Diabetes is an increasingly prevalent yet under-recognised health crisis in Africa, driven by demographic and socioeconomic transitions. In 2021, 24 million adults in the region were living with diabetes, and this figure is expected to increase by 129% by 2045.
This publication provides guidance for planning country-specific programming to achieve the triple elimination of mother-to-child (or vertical) transmission of HIV, syphilis and hepatitis B virus. It is based on the WHO Triple Elimination Framework, which promotes an integrated, person-centred appro...ach to efficiently and holistically prevent transmission of these infections from mothers to their infants along four pillars.
more
This operational guidance provides a structured approach to support countries in sustaining priority services for HIV, viral hepatitis and sexually transmitted infections in the context of reduced external funding. The guidance is intended for national governments, public health programmes, communit...y-led organizations, civil society, technical partners and donors working to safeguard priority services, support phased adaptation, protect health outcomes and preserve hard-won gains.
more
The new WHO guidelines provide clinical management recommendations for four of the most widespread arboviruses affecting humans: dengue, chikungunya, Zika, and yellow fever.
An integrated approach is vital, as these four diseases often present with similar symptoms, especially in the early stages... of infection, and multiple arboviruses may circulate simultaneously in certain regions. This makes clinical differentiation challenging, particularly where diagnostic testing is not readily available.
This guideline is available in online format on the MAGICapp platform
more
This guidance synthesizes current evidence on dengue laboratory testing and diagnostics and provides practical recommendations for laboratories, clinicians, public health officials, and programme managers involved in dengue diagnosis, surveillance, and control, in the context of the global emergency.... It includes a diagnostic algorithm for suspected cases, outlining appropriate testing methods based on days post symptom onset.
more
The global cholera statistics for 2024, showing an increase in both the number of people who fell sick and died from the disease.
Reported cholera cases rose by 5% and deaths by 50% in 2024 compared to 2023, with more than 6000 people dying from a disease that is both preventable and treatable. Whi...le these numbers are themselves alarming, they are underestimates of the true burden of cholera.
Weekly epidemiological record WER No 36, 2025, 100, 347–364
more
It is estimated that around 2 billion people worldwide do not have access to essential medicines. Access to medicines in the Eastern Mediterranean Region varies among countries, depending on their income level and allocation of domestic resources to medicine and vaccine procurement. Access to safe a...nd effective antibiotics remains a major challenge, especially for low- and middleincome countries. Barriers to access include high prices for new products, weak regulatory systems, substandard and falsified antibiotics, shortages of essential antimicrobials and inefficient procurement and supply management systems.
more
Centre de traitement des infections respiratoires aiguës sévères : manuel pratique pour la mise en place et la gestion d’un centre de traitement des IRAS et d’une unité de dépistage des IRAS dans les établissements de soins
Pre-exposure prophylaxis (PrEP)
Policy Brief
November 2015